Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer
NCT ID: NCT01776138
Last Updated: 2021-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
103 participants
OBSERVATIONAL
2012-07-23
2021-09-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504
Prognostic Biomarkers in Patients With Urothelial Carcinoma
NCT04872036
Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy
NCT02039310
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
NCT02968732
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
NCT06138561
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary objectives will include an exploration of the association between functional status, surgical complications, and laboratory markers with complications and survival. In addition, exploratory analyses may evaluate the association of expression of the senescence marker p16INK4a and the morbidity and mortality associated with treatment.
Patients will be asked to complete a Geriatric Assessment (GA) and FACT-Bl serially over the course of the study in order to evaluate their functional status and quality of life during the course of treatment. Additionally, complications will be tracked in an inpatient and outpatient setting using the Memorial Sloan Kettering Cancer Center (MSKCC) complications grading system.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bladder Cancer Patients
Patients diagnoses with bladder cancer who are eligible to undergo treatment.
Collect Blood and Survey Instruments
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collect Blood and Survey Instruments
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed, IRB approved written informed consent.
* Completion of baseline Geriatric Assessment
Exclusion Criteria
* Inability to comply with study for any other reason than language
* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UNC Lineberger Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angela Smith, MD
Role: PRINCIPAL_INVESTIGATOR
University of North Carolina Lineberger Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-0577
Identifier Type: OTHER
Identifier Source: secondary_id
LCCC1206
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.